Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | KDM6A | O15550 | 1/20 | 0.62 |
| ▸ | KDM4A | O75164 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | KDM5C | P41229 | 1/20 | 0.62 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.62 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.62 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | COMT | P21964 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6997040 | 0.98 | KDM4E (0.60) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL4546216 | 0.85 | KDM4E (0.58) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL869287 | 0.84 | KDM4E (0.62) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL18117860 | 0.82 | KDM4E (0.60) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL10404502 | 0.82 | KDM4E (0.60) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL8615538 | 0.82 | KDM4E (0.60) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL9700190 | 0.79 | KDM4E (0.56) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL867532 | 0.78 | KDM4E (0.55) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL12949554 | 0.78 | KDM4E (0.55) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| Deferiprone SCHEMBL6400926 | 0.78 | KDM4E (0.76) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984934-B1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNAT LTD COMPANY NO 26 (GB) | 2003-01-08 | — | — | EP | claimed |
| US-RE35948-E | TREATING TOXIC METAL CONCENTRATION BY ADMINISTERING N-SUBSTITUTED 3-HYDROXYPYRID-2-ONE OR 3-HYDROXYPYRID-4-ONE | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1998-11-03 | — | — | US | claimed |
| US-4585780-A | CHELATION OF HEAVY METALS IN BLOOD | NATIONAL RESEARCH DEVELOPMENT CORP. (GB) | 1986-04-29 | — | — | US | claimed |
| US-8459787-B2 | Aqueous inkjet printing fluid compositions | EASTMAN KODAK COMPANY (US) | 2013-06-11 | — | — | US | disclosed |
| EP-0984934-B1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNAT LTD COMPANY NO 26 (GB) | 2003-01-08 | — | — | EP | disclosed |
| US-6448273-B1 | SUCH AS 2,6-DIMETHOXYMETHYL-1-METHYL-3-BENZYLOXPYRIDIN-4(1H)-ONE; TREATING DISORDERS ASSOCIATED WITH IRON DISTRIBUTION AND IRON DEPENDANT PARASITES; REDUCED LEVELS OF ACTIVE AGENT; SELECTIVE TARGETING TO TISSUES AND LIVER; METABOLIC STABILITY | BTG INTERNATIONAL LIMITED (GB) | 2002-09-10 | — | — | US | disclosed |
| US-20020068758-A1 | Novel orally active iron (III) chelators | BTG INTERNATIONAL LIMITED. | 2002-06-06 | — | — | US | disclosed |
| EP-0984934-A1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNATIONAL LIMITED (Company No. 2664412) (GB) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054138-A1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNATIONAL LIMITED (GB) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068758-A1 | Novel orally active iron (III) chelators | HAMP, HRH2, GRHPR | KDM4E 1012/4885KDM6A 1351/4885KDM4A 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.